OBJECTIVE: To evaluate the predictive value of tumor volume (TV), tumor percentage (TP), and number of tumor foci (NF) in patients with prostate cancer.
The prognostic relevance of TV, TP, and NF as predictors of biochemical recurrence (BCR) following radical prostatectomy (RPE) is controversial.
PATIENTS AND METHODS: The cohort consisted of 758 referred subjects who underwent RPE between 2000 and 2005 at the University of Muenster. The mean time of follow-up was 62 months. TV, TP, and NF were estimated visually with the assistance of a pathologic mapping grid for embedded whole-mount RPE specimens. In addition, TV and TP were assessed in a categorized fashion by using quartiles as cutoff points. Subgroup analyses for high- and low-risk patients using univariate and multivariate Cox proportional hazard analyses for BCR were performed.
RESULTS: TV, TP, and NF were strongly related to tumor stage, Gleason score, surgical margin status, and preoperative prostate-specific antigen (PSA). In univariate analysis, all pathologic parameters including TV, TP, and NF were predictive for BCR. In multivariate analysis, only TP, tumor stage, and PSA level were independent predictors. In subgroup analysis, TP was an independent predictor for BCR in the high-risk group but not in the low-risk group.
CONCLUSIONS: TP, but not TV or NF, was found to be an independent predictor for BCR in patients after RPE. TP seems to be more relevant in high-risk patients (i.e., any of the following:>pT2, Gleason score>6, or PSA>20ng/ml).
Written by:
Hinkelammert R, Eminaga O, Bettendorf O, Eltze E, Abbas M, Hertle L, Semjonow A. Are you the author?
Prostate Center, Department of Urology, University Hospital Muenster, Muenster, Germany; Department of Urology, University Hospital Cologne, Cologne, Germany; Institute of Pathology, Schüttorf, Germany; Institute of Pathology, Saarbrücken, Germany; Institute of Pathology, Medizinische Hochschule, Hannover, Germany; Prostate Center, Department of Urology, University Hospital Muenster, Muenster, Germany.
Reference: Urol Oncol. 2013 Dec 11. pii: S1078-1439(13)00405-5.
doi: 10.1016/j.urolonc.2013.10.001
PubMed Abstract
PMID: 24332639
UroToday.com Prostate Cancer Section
